Intercept Pharmaceuticals, Inc.
ICPT
ICPT was delisted on the 7th of November, 2023.
0 hedge funds and large institutions have $0 invested in Intercept Pharmaceuticals, Inc. in 2023 Q4 according to their latest regulatory filings, with 0 funds opening new positions, 0 increasing their positions, 0 reducing their positions, and 146 closing their positions.
93.29% less ownership
Funds ownership: 93.29% → 0% (-93%)
100% less funds holding
Funds holding: 146 → 0 (-146)
100% less funds holding in top 10
Funds holding in top 10: 3 → 0 (-3)
100% less capital inflows, than outflows
Capital inflows: $0 | Capital outflows: $725M
100% less first-time investments, than exits
New positions opened: 0 | Existing positions closed: 146
Top Buyers
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
-$78.1M |
| 2 |
State Street
Boston,
Massachusetts
|
-$59.3M |
| 3 |
UBS Group
Zurich,
Switzerland
|
-$55.6M |
| 4 |
Magnetar Financial
Evanston,
Illinois
|
-$44.6M |
| 5 |
AAM
Alpine Associates Management
Palm Beach,
Florida
|
-$40.8M |
ICPT Hedge Fund Activity: Q4 2023 in Review
0 of the 6,873 institutional investors tracked by Wall St. Rank reported a position in Intercept Pharmaceuticals, Inc. (ICPT) for Q4 2023, worth a combined $0 — down 100% from $725M a quarter earlier.
Sellers outnumbered buyers: 146 funds closed out of ICPT and 0 opened new positions — a net loss of 146 holders — while 0 trimmed existing stakes and 0 added.
The largest seller was BlackRock, exiting entirely with an estimated $78.1M sold.
- 0 institutional investors held Intercept Pharmaceuticals, Inc. (ICPT) as of Q4 2023, down from 146 in Q3 2023.
- Funds reported $0 of Intercept Pharmaceuticals, Inc. stock for Q4 2023, down 100% quarter-over-quarter.
- 0 funds opened new Intercept Pharmaceuticals, Inc. positions in Q4 2023 and 146 closed out, a net change of -146 holders.
- The largest Intercept Pharmaceuticals, Inc. seller in Q4 2023 was BlackRock, an estimated $78.1M sold.
Based on aggregated 13F filings for Q4 2023.